medigraphic.com
ISSN 2007-8013 (Print)
Órgano oficial de la Universidad Autónoma de Sinaloa

2023, Number 4

<< Back Next >>

Rev Med UAS 2023; 13 (4)

Dermatofibrosarcoma Protuberans

Rubio-Rodríguez MZ, Muñoz-Estrada VF, Valenzuela-Marrufo RA

Language: Spanish
References: 30
Page: 453-462
PDF size: 193.76 Kb.


ABSTRACT

Dermatofibrosarcoma protuberans (DFSP) is a cutaneous sarcoma derived from fibroblasts. It is more frequent in men between the third and fourth decade of life. This tumor may present as a pink plaque or nodule that resembles a scar. The diagnosis is based on physical examination and is confirmed by histopathological and immunohistochemical study. The treatment of choice is surgery with wide lesion-free margins; However, radiotherapy or a multikinase inhibitor such as imatinib can be chosen. The prognosis depends on the advanced age of the patient, the recurrence of the disease, its topography and the histological type.


REFERENCES

  1. Larbcharoensub N, Kayankarnnavee J,Sanpaphant S, Kiranantawat K,Wirojtananugoon C, Sirikulchayanonta V.Clinicopathological features ofdermatofibrosarcoma protuberans. OncolLett. 2016;11(1):661–7.

  2. Hao X, Billings SD, Wu F, Stultz TW, ProcopGW, Mirkin G, et al. DermatofibrosarcomaProtuberans : Update on the Diagnosis andTreatment. J Clin Med. 2020 Jun 5;9(6):1752

  3. Rouhani P, Fletcher CDM, Devesa SS, ToroJR. Cutaneous soft tissue sarcomaincidence patterns in the U.S.: An analysis of12,114 cases. Cancer. 2008;113(3):616–27.

  4. Kreicher KL, Kurlander DE, Gittleman HR,Barnholtz-sloan JS, Bordeaux JS. Incidenceand Survival of PrimaryDermatofibrosarcoma Protuberans in theUnited States. Dermatol Surg. 2016 Jan;42Suppl 1:S24-31

  5. Kuzel P, Metelitsa AI, Dover DC, SalopekTG. Epidemiology of dermatofibrosarcomaprotuberans in Alberta, Canada, from 1988to 2007. Dermatologic Surg.2012;38(9):1461–8.

  6. Ibarra-Morales D, Moreno-López LM M-PP.Dermatofibrosarcoma protuberans:correlación clínico-patológica. Revisión de43 años. Dermatol Rev Mex.2022;66(3):331–40.

  7. Sirvent N, Maire G, Pedeutour F. Genetics ofdermatofibrosarcoma protuberans family oftumors: From ring chromosomes to tyrosinekinase inhibitor treatment. GenesChromosom Cancer. 2003;37(1):1–19.

  8. Serra-Guillén C, Llombart B, Sanmartín O.Dermatofibrosarcoma protuberans. ActasDermosifiliogr . 2012;103(9):762–77.

  9. Barrera J, Acosta A, Trujillo L.Dermatofibrosarcoma protuberans. RevColomb Cancerol. 2019;23(3):99–109.

  10. Torreggiani WC, Al-Ismail K, Munk PL,Nicolaou S, O'Connell JX, Knowling MA.Dermatofibrosarcoma protuberans: MRimaging features. AJR Am J Roentgenol.2002 Apr;178(4):989-93

  11. Serra-Guillén C, Sanmartín O, Llombart B,Nagore E, Deltoro C, Martín I, et al.Correlation between preoperative magneticresonance imaging and surgical marginswith modified mohs for dermatofibrosarcomaprotuberans. Dermatologic Surg.2011;37(11):1638–45.

  12. Schmults CD. Dermatofibrosarcomaprotuberans. NCCN Clin Pract Guidel Oncol.2023;1.

  13. Ugurel S, Kortmann RD, Mohr P, Mentzel T,Garbe C, Breuninger H, et al. S1 guidelinesfor dermatofibrosarcoma protuberans(DFSP) – update 2018. JDDG - J Ger SocDermatol. 2019;663–8.

  14. Akram J, Wooler G, Lock-Andersen J.Dermatofibrosarcoma protuberans: Clinicalseries, national Danish incidence data andsuggested guidelines. J Plast Surg HandSurg. 2014;48(1):67–73.

  15. Wiesmueller F, Agaimy A, Perrakis A,Arkudas A, Horch RE, Grützmann R, VassosN. Dermatofibrosarcoma protuberans:surgical management of a challengingmesenchymal tumor. World J Surg Oncol.2019 May 28;17(1):90

  16. Huis EA, Grünhagen DJ, Van Coevorden F,Smith MJ, van Akkooi AC, Wouters MWJM,et al. Adequate surgical margins fordermatofibrosarcoma protuberans – A multicentreanalysis. Eur J Surg Oncol .2021;47(2):436–42.

  17. Snow H, Davies E, Strauss DC, Smith M,Hayes AJ. Conservative Re-excision is aSafe and Simple Alternative to RadicalResection in Revision Surgery forDermatofibrosarcoma Protuberans. AnnSurg Oncol 2020;27(3):919–23.

  18. Decanter G, Stoeckle E, Honore C, MeeusP, Mattei JC, Dubray-Longeras P, et al.Watch and Wait Approach for Re-excisionAfter Unplanned Yet MacroscopicallyComplete Excision of Extremity andSuperficial Truncal Soft Tissue Sarcoma isSafe and Does Not Affect Metastatic Risk orAmputation Rate. Ann Surg Oncol.2019;26(11):3526–34.

  19. Chen Y, Jiang G. Association betweensurgical excision margins and outcomes inpatients with dermatofibrosarcomaprotuberans: A meta-analysis. DermatolTher. 2021;34(4):1–8.

  20. Allen A, Ahn C, Sangüeza OP.Dermatofibrosarcoma Protuberans.Dermatol Clin . 2019;37(4):483–8.

  21. Nieto-Benito LM, Ciudad-Blanco C,Sanmartin-Jimenez O, Garces JR,Rodríguez-Prieto MA, Vilarrasa E, et al.Mohs micrographic surgery indermatofibrosarcoma protuberans: Rate andrisk factors for recurrence in a prospectivecohort study from the Spanish Registry ofMohs Surgery (REGESMOHS) and reviewof the literature. Exp Dermatol.2021;30(5):717–22.

  22. González Medina E, Lacy Niebla R, BoetaÁngeles L,Vega Memije M.Dermatofibrosarcoma protuberans: unarevisión. Dermatol C . 2015;13(2):149–56.

  23. Bogucki B, Neuhaus I, Hurst EA.Dermatofibrosarcoma protuberans: A reviewof the literature. Dermatol Surg.2012;38(4):537–51.

  24. Llombart B, Serra C, Requena C, Alsina M,Morgado-Carrasco D, Través V, et al.Guidelines for Diagnosis and Treatment ofCutaneous Sarcomas:Dermatofibrosarcoma Protuberans. ActasDermosifiliogr. 2018;109(10):868–77.

  25. Rao E, Weiss B, Fukami M, Rump A, NieslerB, Mertz A. © 199 7 Nature Publishing Grouphttp://www.nature.com/naturegenetics. NatGenet. 1997;15:57–61.

  26. Ugurel S, Becker JC. Imatinib inDermatofibrosarcoma: Targeted Therapy orImmunotherapy? J Invest Dermatol.2017;137(2):277–9.

  27. Castle KO, Guadagnolo BA, Tsai CJ, FeigBW, Zagars GK. Dermatofibrosarcomaprotuberans: Long-term outcomes of 53patients treated with conservative surgeryand radiation therapy. Int J Radiat Oncol BiolPhys . 2013;86(3):585–90.

  28. Mendenhall WM, Zlotecki RA, ScarboroughMT. Dermatofibrosarcoma protuberans.Cancer. 2004;101(11):2503–8.

  29. Chen YT, Tu WT, Lee WR, Huang YC. Theefficacy of adjuvant radiotherapy indermatofibrosarcoma protuberans: asystemic review and meta-analysis. J EurAcad Dermatol Venereol. 2016;30(7):1107–14.

  30. Kim BJ, Kim H, Jin US, Minn KW, Chang H.Wide Local Excision forDermatofibrosarcoma Protuberans: ASingle-Center Series of 90 Patients. BiomedRes Int. 2015;2015.




2020     |     www.medigraphic.com